Role of PARP inhibitors in cancer biology and therapy.

Role of PARP inhibitors in cancer biology and therapy.
复制标题

DOI:
10.2174/092986712802002464
复制
发表时间:
2012
影响因子:
4.1
通讯作者:
Tawbi H
Tawbi H
中科院分区:
医学3区
文献类型:
--
作者:
Davar D;Beumer JH;Hamieh L;Tawbi H

文献摘要

参考文献

被引文献

相似文献

对DNA修复机制及其作为肿瘤治疗靶点的潜在价值的深入理解预示着聚(ADP-核糖)聚合酶(PARP)抑制剂的临床开发。虽然最初开发利用与DNA修复缺陷相关的癌症模型中的合成致死性,但我们对PARP生物学的新兴知识已导致这些药物在具有选择的化疗药物的癌症和非恶性疾病中被利用。在这篇综述文章中,我们简要回顾了DNA修复的机制和PARP抑制剂的临床前开发,然后深入讨论各种PARP抑制剂的临床开发。
Deeper understanding of DNA repair mechanisms and their potential value as therapeutic targets in oncology heralded the clinical development of poly (ADP-ribose) polymerase (PARP) inhibitors. Although initially developed to exploit synthetic lethality in models of cancer associated with defective DNA repair, our burgeoning knowledge of PARP biology has resulted in these agents being exploited both in cancer with select chemotherapeutic agents and in non-malignant diseases. In this review article, we briefly review the mechanisms of DNA repair and pre-clinical development of PARP inhibitors before discussing the clinical development of the various PARP inhibitors in depth.
DOI: 10.1017/s146239940500904x
发表时间: 2005-03-30
影响因子: 6.2
作者:
Curtin, Nicola J.
通讯作者: Curtin, Nicola J.
DOI: 10.1158/1078-0432.ccr-09-0398
发表时间: 2009-10-01
影响因子: 11.5
作者:
Ali, Majid;Telfer, Brian A.;Williams, Kaye J.
通讯作者: Williams, Kaye J.
DOI: 10.1016/s0140-6736(10)60893-8
发表时间: 2010-07-24
期刊: LANCET
影响因子: 168.9
作者:
Audeh, M. William;Carmichael, James;Tutt, Andrew
通讯作者: Tutt, Andrew
DOI: 10.1016/0006-291x(63)90024-x
发表时间: 1963-01-01
影响因子: 3.1
作者:
CHAMBON, P;MANDEL, P;WEILL, JD
通讯作者: WEILL, JD
DOI: 10.1111/j.1365-2567.2008.02921.x
发表时间: 2009-06-01
期刊: IMMUNOLOGY
影响因子: 6.4
作者:
Ambrose, Helen E.;Willimott, Shaun;Wagner, Simon D.
通讯作者: Wagner, Simon D.